247 results about "Tromethamine" patented technology

A pharmaceutical oral formulation for delivering nicotine in any form to a subject by transmucosal uptake in the oral cavity comprising nicotine in any form, wherein said oral formulation is buffered with at least trometamol. Also contemplated is a method for the oral delivery of nicotine in any form, a method for the reduction of the urge to smoke or use tobacco as well as methods for manufacturing the oral formulation, the use of the oral formulation for obtaining transmucosal uptake of nicotine in the oral cavity of a subject, and use of nicotine for the production of an oral formulation for the treatment of a disease selected from the group consisting of tobacco or nicotine dependence, Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control.

Disclosed is an ophthalmic composition containing (A) not less than 50,000 units/100 mL of vitamin A, (B) not less than 0.4 W/V % of a polyoxyethylene polyoxypropylene glycol, and (C) trometamol.

The invention provides sacubitril derivatives and medicine compositions, preparation methods and application thereof and belongs to the fields of medicine compounds and preparation thereof. The sacubitril derivatives comprise sacubitril lithium salt, sacubitril kali salt, sacubitril magnesium salt, sacubitril calcium salt, sacubitril strontium salt, sacubitril zinc salt, sacubitril ferric salt, sacubitril ammonium salt, sacubitril diethylamine salt, sacubitril ethylenediamine salt, sacubitril piperazine salt, sacubitril N-(2-ethoxyl)-pyrrolidine salt, sacubitril choline salt, sacubitril cholamine salt, sacubitril diethanol amine salt, sacubitril triethanolamine salt, sacubitril tromethamine salt, sacubitril meglumine salt, sacubitril diisopropylamine salt, sacubitril tert-butylamine salt, sacubitril N, N'-bis-benzyl ethylenediamine salt, sacubitril L-lysine salt, sacubitril L-arginine salt or sacubitril L-histidine salt.

Efforts to extend myocardial preservation for transplantation by perfusion with prior crystalloid based solutions have been limited by edema and compromised function. Hypothermic perfusion preservation with a polyethylene glycol (PEG) conjugated hemoglobin solution extends preservation times. The polyethylene glycol (PEG) conjugated hemoglobin solution comprises PEG-Hb, and at least one of the constituents selected from the group of human albumin, dextrose, heparin sodium, lidocaine HCl, MgSO₄, KCl, CaCl₂, Tromethamine (THAM) solution, NaCl, NaHCO₃, and Na₂HPO₄/NaH₂PO₄. Comparison of cardiac function after continuous perfusion using a hypocalcemic normokalemic crystalloid perfusate is made with and without the addition of PEG-Hemoglobin (Hb).

The invention discloses a whole blood genomic DNA high-flux plate type extracting kit and an extracting method, and relates to the technical field of biology. The whole blood genomic DNA high-flux plate type extracting kit comprises a lysate 1, a lysate 2, a combination liquid, and magnetic beads, wherein the lysate 1 comprises the following components: 2 to 8 mol/L guanidine hydrochloride, 1 to 10 percent of triton-100 (V/V), 1 to 10 percent of Tween-20 (V/V), 1 to 10 percent of chelex-100 (m/V), 2 to 10 mmol/L ethylene diamine tetraacetic acid and 20 to 100 mmol/L tromethamine, wherein the pH is regulated to be 4.5 by hydrochloric acid, and the solvent is deionized water; the lysate 2 comprises the following components: 20 mg/ml protease K and 50 mmol/L trimethyl aminomethane, wherein the pH is regulated to be 8.0 by the hydrochloric acid; the combination liquid comprises the following components: 1 to 3 mol/L sodium chloride and 40 to 90 percent of isopropyl alcohol (V/V), wherein the solvent is the deionized water. According to the whole blood genomic DNA high-flux plate type extracting kit and the extracting method, the purpose of extracting 96 samples simultaneously within 50 minutes can be achieved without centrifuging or matching an automatic instrument.

The invention belongs to the technical field of medicine, in particular to a drug composition of gargle which contains sodium dichlorophenolate and can relieve pain and be anti-inflammatory for the oral inflammation disease; wherein the drug composition comprises the following components by percentage: 0.10 to 30 percent of sodium dichlorophenolate hydroxypropyl-Beta-cyclodextrin inclusion (equal to 0.065 to 0.20 percent of concentration of sodium dichlorophenolate), 0.01 to 0.10 percent of lidocaine hydrochloride, 0.10 to 5.0 percent of borax, 0.1 to 2.0 percent of boric acid, 0.1 to 10 percent of glycerin, 0.10 to 5.0 percent of sodium bicarbonate, 0.001 to 0.10 percent of vitamin B12, 0.02 to 1.0 percent of tromethamine, 0.01 to 5.0 percent of sucralose, 0.10 to 5.0 percent of peppermint essence and 0.01 to 1.0 percent of sodium benzoate; a proper amount of pharmaceutical caramel color and water for injection is added till to reach the needed weight/volume concentration. All the above components are weighted by weight/volume percentage; the aqueous solution of the composition has the pH value of 6.5 to 9.0. The composition has little thrill to oral mucosa, stable storage for long time and good biological tolerance and has fast and long-lasting curative effect for relieving pain and being anti-inflammatory to the oral inflammation disease.

The invention provides a method for reducing esophageal irritation associated with alpha-lipoic acid upon oral administration through the use of the trometamol salt of alpha-lipoic acid. The present invention also provides for the increased solubility of alpha-lipoic acid through the use of the trometamol salt of alpha-lipoic acid. The trometamol salt of alpha-lipoic acid, as provided by the present invention can be used as a substitute for regular, non-salt forms alpha-lipoic acid in dietary supplement compositions.

The present invention relates to a non-steroidal anti-inflammatory drug of ketorolac tromethamine salt, which has the functions of strong acesodyne, moderate anti-inflammation and antipyresis. The present invention applies a synthesis route preparing the compound ketorolac tromethamine salt, the technique applies an one-pot method, the reaction process from 2-benzoyl pyrrole to the ketorolac tromethamine salt can be continuously carried out, extraction and purification are not needed, materials can be easily obtained, labor intensity is reduced, the operational environment is improved, the cost of industrialized production is greatly reduced, environmental pollution is reduced, the loss of materials and products is reduced, and the yield rate is increased.

The invention discloses a preparation method of fosfomycin amine salt, which comprises the following steps of: in organic solvent, enabling fosfomycin phenylethylamine salt to react with isocyanate, isothiocyanate, ketene, dipolymer of isocyanate, dipolymer of isothiocyanate or dipolymer of ketene, and tromethamine; or in the organic solvent, enabling fosfomycin bistromethamine to react with isocyanate, isothiocyanate, ketene, dipolymer of isocyanate, dipolymer of isothiocyanate or dipolymer of ketene. The preparation method provided by the invention has the advantages that the fosfomycin amine salt can be prepared in one step only, a low-temperature ion exchange column is not required, the yield is high, the cost is low, the waste gas, waste water and waste residue are less, the reaction conditions are moderate, the energy consumption is low, the operation is convenient to conduct and the method is suitable for industrial production.

The invention provides a synthesis method for 1,2,4-tromethamine, comprising the following steps: the mixed solution of butene diol, tungsten acid and N-methyl morpholine, and epoxidizing agent are mixed through a mixer which is provided with two channel nozzles and arranged at the top part of a reactor, and then enter the reactor for reaction; the material in the reactor is sent to a nozzle at the top part of the reactor through a circulating pump for recycling use to collect epoxide; the epoxidizing agent is selected from oxygen-rich gases; in the presence of catalysts, the epoxide and ethanol go through hydrogenation reaction, then the 1,2,4-tromethamine is collected. The invention adopts oxygen-rich gas as epoxidizing agent and avoids the introduction of unnecessary media in the reaction system through the pre-mixing in a mixer provided with two channel nozzles; besides, the method of the invention has easily-controlled reaction temperature, less equipment investment and mild operating conditions, which does not use the traditional mercury catalyst and has no pollution to the environment; the reaction yield of the method can reach more than 95%, so the method is easy in industrialized implementation.

The invention discloses a pemetrexed salt and a preparation method and use thereof, the pemetrexed salt can be dipotassium salt, arginine salt, heme-L-lysinate salt and tromethamine salt of the pemetrexed, and the pemetrexed salt can be used for treatment of various cancers such as mesothelioma, lung cancer and the like.

The potassium, sodium, ammonium, lysine, diethylamine, tromethamine (TRIS), piperazine, ethylenediamine and ethanolamine salt of a compound of general formula (I): wherein R<1> is halo or cyano; R<2> is C1-C4 alkyl; and R<3> is quinolyl or phenyl substituted with methane sulfonyl; can be synthesised by a novel method and are substantially more soluble than the parent free acids in a range of solvents.

The invention discloses an injection octreotide acetate lyophilized composition and a preparation method thereof. The lyophilized composition comprises octreotide acetate, tromethamine and maleic acid. The preparation method comprises the following steps: weighing octreotide acetate and tromethamine, adding into injection water which is cooled to 10-20 DEG C, and stirring to dissolve; regulating the pH of the liquid medicine to be 4.0-5.0 with maleic acid, filtering, filling and lyophilizing. Compared with the prior art, the lyophilized composition is stable in quality, few in auxiliary varieties and simple in preparation process.

The invention discloses a moisture-retaining body cream. The moisture-retaining body cream employs tromethamine to adjust the acid-base property of a body, utilizes glycolic acid to exert exfoliating and whitening effect on the skin, has good moisture-retaining and moisture-supplementing effect due to usage of hyaluronic acid and arginine, exerts good calming and astringing effect on the skin in virtue of sesame flower extract and has good soothing and anti-inflammation effect on the effect as sensitive plant extract and cactus flower extract are used. The moisture-retaining body cream is especially applicable to skin moistening in autumn and winter.

The invention provides an ozagrel salt which is stable, has functions of inhibiting platelet aggregation and removing blood-vessel convulsion, has good water solubility, and is prepared into a compound suitable for clinical application. The new compound is ozagrel tromethamine; and the ozagrel and the tromethamine are prepared by reaction in a solvent. The compound has good water solubility, strong and long-term stability, and the functions of inhibiting platelet aggregation and removing blood-vessel convulsion.

The invention discloses a sub-muscular essence and a preparation method thereof, belongs to the technical field of skin care products, and solves the problem an anti-aging function cannot be effectively achieved in the prior art. The sub-muscular essence is prepared from a group A, a group B, a group C, a group D and the balance water, the group A comprises, in weight percent, 1-4% of glycerin polyether-26, 1-4% of 1, 3-propylene glycol, 1-4% of moisturizing agents A, 1-4% of moisturizing agents B, 1-4% of conditioners A, 1-4% of solvents A, 0.4-2% of 1, 2-hexylene glycol, 0.4-1% of p-hydroxyacetophenone, 0.05-0.5% of ammonium acrylate dimethyl taurine/VP copolymers, 0.03-0.5% of xanthan gum and 0.05-0.15% of EDTA (ethylenediamine tetraacetic acid) disodium salt, the group B comprises, inweight percent, 1-6% of butylene glycol and 0.05-0.4% of carbomer, the group B comprises, in weight percent, 0.05-0.4% of tromethamine, and a group D comprises active substances. According to the sub-muscular essence, excitation of self-activating repair is matched with enhancement of skin barriers, so that overall anti-aging effects are achieved.

The invention discloses application of tromethamine in drugs for treating hyperuricemia and related disease. The tromethamine can serve as a drug in application of treating hyperuricemia, urinary system uric acid calculi and gout, an adult takes 1-7 g of the dose every day, and the medication method is intravenous drip. The tromethamine is used for promoting uric acid to dissolve and discharge, no inorganic ions exist because the tromethamine is organic amine alkali, the inhibiting effect of the inorganic ions can be avoided or weakened, the effect of the tromethamine for promoting uric acid to dissolve and discharge is better than that of sodium bicarbonate, and the tromethamine can be used for treating hyperuricemia, urinary system uric acid calculi and gout. Besides, the tromethamine is a foreign substance, an organic body cannot produce the tromethamine substance, and accordingly, the concentration of the tromethamine in the body is better to control compared with the sodium bicarbonate in the medication process.

This invention discloses trometamol salts of cillin compounds, or their hydrates that can be used to treat bacillosis. As hown in formula 1, the salts comprise trometamol salts of azlocillin, amoxicillin, ampicillin, oxazacillin, furbucillin, cloxacillin, mezlocillin, mecillinam, piperacillin, ticarcillin, floxacillin, hetacillin, cloxacillin and penicillin. This invention provides drug compositions with the salts shown in formula 1 as the active components, and their application in drugs for treating bacillosis.

Provided is a synthetic method of water-solubility biocompatibility monodisperse spherical gold nanometer crystals. The synthetic method of the water-solubility biocompatibility monodisperse spherical gold nanometer crystals comprises the following steps (1) using ultra-pure water to prepare a sodium citrate solution, a chloroauric acid solution, a silver nitrate solution and a glutathione solution or a tromethamine solution; (2) mixing the ultra-pure water, the sodium citrate solution, the chloroauric acid solution and the silver nitrate solution together to form a premixed solution, adding the glutathione solution or the tromethamine solution into the premixed solution to form a mixed solution; when the silver nitrate solution and the ultra-pure water are not used, solutions does not need to be mixed; (3) rapidly injecting the mixed solution into the boiling ultra-pure water which is used in a reaction, or directly injecting the solutions into the boiling ultra-pure water which is used in the reaction; and (4) carrying out heating reflux on the mixture, and naturally cooling extraction to room temperature. The synthetic method of the water-solubility biocompatibility monodisperse spherical gold nanometer crystals has the advantages of being simple in operation, good in repeatability, capable of obtaining the water-solubility biocompatibility monodisperse spherical gold nanometer crystals which are high in quality and can not be obtained in other existing methods.